CEL-SCI Announces $10 Million Stock Offering at $9 Per Share

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical-stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share is being sold at a public offering price of $9.00 per share, with total gross proceeds expected to be approximately $10 million before deducting fees and expenses. The offering is expected to close on August 29, 2025, subject to customary closing conditions.

The Company plans to use the net proceeds to fund the continued development of Multikine, for general corporate purposes, and as working capital.

ThinkEquity is acting as the sole placement agent for the offering.

The securities are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), which was filed with the U.S. Securities and Exchange Commission (SEC) on July 3, 2025, and became effective on August 12, 2025. A final prospectus supplement and accompanying prospectus will be filed with the SEC and available on its website at www.sec.gov. Copies may also be obtained from ThinkEquity, located at 17 State Street, 41st Floor, New York, New York 10004.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under applicable securities laws.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy, and chemotherapy have taken place should have the greatest impact on survival. Multikine is designed to help the immune system “target” the tumor when the immune system is still intact, potentially mounting a more effective attack on the tumor.

Multikine (Leukocyte Interleukin, Injection), administered after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

CEL-SCI operates in Vienna, Virginia, and near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include words such as “intends,” “believes,” “anticipates,” “plans,” and “expects,” and similar expressions. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, the inability to duplicate clinical results, timely development of safe and effective products, receiving regulatory approvals, manufacturing challenges, and the risk factors outlined in CEL-SCI’s SEC filings, including its Form 10-K for the year ended September 30, 2024. The Company assumes no obligation to publicly revise forward-looking statements to reflect events or circumstances following this release.

*Multikine (Leukocyte Interleukin, Injection) is a trademark registered by CEL-SCI for this investigational therapy. It has not been licensed or approved for sale, barter, or exchange by the FDA or any other regulatory agency, and its safety or efficacy has not been established for any use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827425347/en/

For Investor Relations Inquiries:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460

Source: CEL-SCI Corporation